Nipro (NPRRF) Cash And Cash Equivalents : $552 Mil (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Nipro Cash And Cash Equivalents?

Nipro's quarterly cash and cash equivalents declined from Jun. 2023 ($622.94 Mil) to Sep. 2023 ($589.94 Mil) but then stayed the same from Sep. 2023 ($589.94 Mil) to Dec. 2023 ($551.63 Mil).

Nipro's annual cash and cash equivalents declined from Mar. 2022 ($804.05 Mil) to Mar. 2023 ($670.92 Mil) and declined from Mar. 2023 ($670.92 Mil) to Mar. 2024 ($665.25 Mil).

Nipro Cash And Cash Equivalents Historical Data

The historical data trend for Nipro's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nipro Cash And Cash Equivalents Chart

Nipro Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Cash And Cash Equivalents

Get a 7-Day Free Trial

890.94

830.49

804.05

670.92

665.25

Nipro Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															670.92	622.94	589.94	551.63	665.25

Nipro Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Nipro (OTCPK:NPRRF) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Nipro Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Nipro's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Nipro (NPRRF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nipro Corp (OTCPK:NPRRF) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

8086:Japan

Address

3-9-3 Honjo-Nishi Kita-ku, Osaka, JPN, 531-8510

Website

http://www.nipro.co.jp

Nipro Corp develops medical devices, most of which are related to dialysis and artificial organs. The firm operates in four segments: medical, pharmaceutical, glass, and other. The medical segment contributes the majority of revenue. It sells products related to injections, infusions, artificial organs, and cell cultures, as well as medical equipment for renal treatment, diabetes, and generic drugs. Renal products contribute the largest proportion of sales within the medical segment. The pharmaceutical segment manufactures pharmaceuticals, including oral drugs and injectables, which are supplied to pharmaceutical companies in Japan. The glass business sells glass products used for medical applications, such as vials and syringes. Nipro generates the majority of its revenue in Japan.

Nipro (NPRRF) Headlines

No Headlines